BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 22102693)

  • 21. Inhibition of v-Abl transformation by p53 and p19ARF.
    Cong F; Zou X; Hinrichs K; Calame K; Goff SP
    Oncogene; 1999 Dec; 18(54):7731-9. PubMed ID: 10618713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RasV12-mediated down-regulation of CCAAT/enhancer binding protein beta in immortalized fibroblasts requires loss of p19Arf and facilitates bypass of oncogene-induced senescence.
    Sebastian T; Johnson PF
    Cancer Res; 2009 Mar; 69(6):2588-98. PubMed ID: 19276382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NF-kappaB: tumor promoter or suppressor?
    Perkins ND
    Trends Cell Biol; 2004 Feb; 14(2):64-9. PubMed ID: 15102437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence.
    Brookes S; Rowe J; Ruas M; Llanos S; Clark PA; Lomax M; James MC; Vatcheva R; Bates S; Vousden KH; Parry D; Gruis N; Smit N; Bergman W; Peters G
    EMBO J; 2002 Jun; 21(12):2936-45. PubMed ID: 12065407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-p53 signaling.
    Shvarts A; Brummelkamp TR; Scheeren F; Koh E; Daley GQ; Spits H; Bernards R
    Genes Dev; 2002 Mar; 16(6):681-6. PubMed ID: 11914273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stepwise neoplastic transformation of a telomerase immortalized fibroblast cell line.
    Zongaro S; de Stanchina E; Colombo T; D'Incalci M; Giulotto E; Mondello C
    Cancer Res; 2005 Dec; 65(24):11411-8. PubMed ID: 16357149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis.
    D'Amico M; Wu K; Di Vizio D; Reutens AT; Stahl M; Fu M; Albanese C; Russell RG; Muller WJ; White M; Negassa A; Lee HW; DePinho RA; Pestell RG
    Cancer Res; 2003 Jun; 63(12):3395-402. PubMed ID: 12810676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis.
    Sharpless NE; Bardeesy N; Lee KH; Carrasco D; Castrillon DH; Aguirre AJ; Wu EA; Horner JW; DePinho RA
    Nature; 2001 Sep; 413(6851):86-91. PubMed ID: 11544531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between p14(ARF)/p16(INK4A) expression and HPV infection in uterine cervical cancer.
    Kanao H; Enomoto T; Ueda Y; Fujita M; Nakashima R; Ueno Y; Miyatake T; Yoshizaki T; Buzard GS; Kimura T; Yoshino K; Murata Y
    Cancer Lett; 2004 Sep; 213(1):31-7. PubMed ID: 15312681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of the expression of p16INK4a and p14ARF by hnRNP A1 and A2 RNA binding proteins: implications for cellular senescence.
    Zhu D; Xu G; Ghandhi S; Hubbard K
    J Cell Physiol; 2002 Oct; 193(1):19-25. PubMed ID: 12209876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of the alternative INK4A proteins in human keratinocyte senescence: evidence for the specific inactivation of p16INK4A upon immortalization.
    Munro J; Stott FJ; Vousden KH; Peters G; Parkinson EK
    Cancer Res; 1999 Jun; 59(11):2516-21. PubMed ID: 10363964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice.
    Krimpenfort P; Quon KC; Mooi WJ; Loonstra A; Berns A
    Nature; 2001 Sep; 413(6851):83-6. PubMed ID: 11544530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [pRB, p53, p16INK4a, senescence and malignant transformation].
    Larsen CJ
    Bull Cancer; 2004 May; 91(5):399-402. PubMed ID: 15281278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt.
    Uhrbom L; Dai C; Celestino JC; Rosenblum MK; Fuller GN; Holland EC
    Cancer Res; 2002 Oct; 62(19):5551-8. PubMed ID: 12359767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of cellular senescence by oncogenic RAS.
    Gupta R; Wajapeyee N
    Methods Mol Biol; 2013; 1048():127-33. PubMed ID: 23929102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The molecular scaffold kinase suppressor of Ras 1 is a modifier of RasV12-induced and replicative senescence.
    Kortum RL; Johnson HJ; Costanzo DL; Volle DJ; Razidlo GL; Fusello AM; Shaw AS; Lewis RE
    Mol Cell Biol; 2006 Mar; 26(6):2202-14. PubMed ID: 16507997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Control of cellular senescence by CPEB.
    Groisman I; Ivshina M; Marin V; Kennedy NJ; Davis RJ; Richter JD
    Genes Dev; 2006 Oct; 20(19):2701-12. PubMed ID: 17015432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferative arrest.
    Rowland BD; Denissov SG; Douma S; Stunnenberg HG; Bernards R; Peeper DS
    Cancer Cell; 2002 Jul; 2(1):55-65. PubMed ID: 12150825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers.
    Jacobs JJ; Keblusek P; Robanus-Maandag E; Kristel P; Lingbeek M; Nederlof PM; van Welsem T; van de Vijver MJ; Koh EY; Daley GQ; van Lohuizen M
    Nat Genet; 2000 Nov; 26(3):291-9. PubMed ID: 11062467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor suppressor p16INK4a determines sensitivity of human cells to transformation by cooperating cellular oncogenes.
    Drayton S; Rowe J; Jones R; Vatcheva R; Cuthbert-Heavens D; Marshall J; Fried M; Peters G
    Cancer Cell; 2003 Oct; 4(4):301-10. PubMed ID: 14585357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.